TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study
Open Access
- 7 March 2023
- journal article
- research article
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 4 (4) , 100494
Abstract
No abstract availableKeywords
Funding Information
- Takeda Science Foundation
- Princess Takamatsu Cancer Research Fund
This publication has 31 references indexed in Scilit:
- Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung CancerJAMA Oncology, 2016
- Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophagesLung Cancer, 2016
- Thyroid Transcription Factor 1 Reprograms Angiogenic Activities of SecretomeScientific Reports, 2016
- Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: A meta-analysisClinica Chimica Acta, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma*Journal of Clinical Pathology, 2015
- The High Diagnostic Accuracy of Combined Test of Thyroid Transcription Factor 1 and Napsin A to Distinguish between Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta-AnalysisPLOS ONE, 2014
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- KrasG12D and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lungJournal of Clinical Investigation, 2012
- Nkx2-1: a novel tumor biomarker of lung cancerJournal of Zhejiang University-SCIENCE B, 2012